K Wave Media, Inc. (Nasdaq: KWM) (“K Wave” or the “Company”) Announces entering into a securities purchase agreement for $500 Million Equity Purchase Facility to Support Bitcoin Treasury Strategy

Notified -

SINTX Technologies Announces Patent Issuance and Formation of Subsidiary to Advance Antimicrobial Applications in the Agribiotech Market

Notified -

Update: Exodus Movement, Inc. Announces Uplist to NYSE American Exchange

Notified -

Fluence Energy, Inc. Announces Closing of Offering of $400.0 Million of Convertible Senior Notes due 2030

Notified -

Safety Shot Expects Approximately 50% Revenue Growth in Q4

Notified -

Io Therapeutics, Inc., announces presentation of data from studies of its RAR gamma agonist compound IRX5010 in treatment of a mouse model of triple negative breast cancer, demonstrating combination treatment effects with an anti-PDL-1 monoclonal antibody

Notified -

Repeat: Thunder Bridge Capital Partners IV, Inc. Announces Effectiveness of Registration Statement and Special Meeting Date for Proposed Business Combination with Coincheck, Inc.

The Sanborn Map Company, Inc. Receives Certification to ISO 9001:2015 Standard

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition

Berman Tabacco Announces Investigation of Evolv Technologies Holdings, Inc. (EVLV, EVLVW) Concerning Accounting Practices

Dark Horse Consulting Group Acquires BioTechLogic, Inc.

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai